Management Team
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.
Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Bob earned a B.A. in Finance from the University of Oklahoma and an M.B.A. from Southern Methodist University.
Byron has contributed in privately and publicly held settings, and has developed, managed, and refined HR functions and programs for start-ups as well as for mature, multi-national organizations.
Byron earned a B.A. in Psychology from the University of California, Berkeley, and an M.A. in Psychology from San Francisco State University. He additionally possesses SPHR certification.
Eric holds an M.B.A. in Finance from the Owen Graduate School of Management at Vanderbilt University and a B.A. in Economics from the University of California, Davis. He is a Chartered Financial Analyst and member of the CFA Institute.
Karen holds a B.A. in Biological Sciences from the University of California, Santa Cruz and an RAC certification in Regulatory Affairs.
Patty holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University. She is a Certified Public Accountant and a Certified Internal Auditor.
Thomas earned a Ph.D. in Molecular & Cell Biology from the University of California, Berkeley and holds a M.S. in Electrical Engineering from the Technische Universitaet Muenchen.
Mark earned a Ph.D. in Experimental Pathology, an M.B.A. and a B.S. in Biochemistry from the University of California, Los Angeles. He is licensed in California as a Clinical Laboratory Scientist (CLS) and holds a Certification of Qualification (COQ) for the State of New York.
Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.
John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.
Board of Directors
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Ignyta, Inc., Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.
From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.
Mr. Rose has an Honors Bachelor of Commerce from McMaster University, and is also a Certified Management Accountant. As a venture capitalist with experience on the boards of several emerging companies, Mr. Rose provides the Singulex Board of Directors with insightful and relevant expertise in both finance and operations. In addition, his financial credentials and experience are of significant value in his service on our governance committee.
Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.
Advisory Board
Richard L. Popp, M.D., has served as Chairman of the Singulex Medical Advisory Board since 2012. Dr. Popp is a Professor of Medicine (Emeritus) at Stanford University School of Medicine, where he has served in numerous academic and administrative positions since joining the Stanford faculty in 1971. He received his medical degree from Johns Hopkins School of Medicine, where he performed his internship and residency before completing further clinical and research training in cardiology at Indiana University Medical Center and Stanford University Hospital.
During his career, Dr. Popp has focused his research on non-invasive methods for diagnosis and treatment of cardiovascular disease, pioneering the development of cardiac ultrasound technology and contributing to the continuous improvement of ultrasonic diagnostic methods. The author of over 270 publications, Dr. Popp is a former President of the American College of Cardiology, The American Society of Echocardiography and The Association of University Cardiologists, and served as Chairman of the American Board of Internal Medicine’s (ABIM) Cardiovascular Diseases Subspecialty Board. Dr. Popp’s continuing interest in the development of technologies that will enhance patient care and potential outcomes, combined with his substantial breadth of experience and achievement in cardiovascular medicine, provides an invaluable contribution to our Medical Advisory Board.